Discover how a groundbreaking cognitive assessment tool is transforming early dementia detection with 99.9% accuracy and what this means for future treatment.

POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fir ...

NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...

Recent advances in molecular biology have provided unprecedented insights into the structure of amyloid fibrils associated ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems long and uncertain, according to a news release.

CIDRAP: Early-Life Infection Burden Continues Throughout Childhood, New Data Reveal New data from researchers in Denmark suggest that children who have a lot of common infections early in life ...

Imagine a world where the mind remains sharp, even as the years pass by. Scientists are on the brink of a breakthrough that ...

Posdinemab is an investigational monoclonal antibody that targets the mid-domain of Alzheimer's disease-specific ...

Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow ...

As Lamborn prepares to leave office, we are most grateful for his support. His support of these signed bills advances the ...